n00_be

🩺 Community Question: Is the “AI five layer cake” framework sufficient to power healthcare AI systems? (The “AI five layer cake” framework: Energy → Chips → Infrastructure → Models → Applications, introduced by Jensen Huang of NVIDIA) Viewpoint A: Yes Healthcare AI aligns with the stack. Energy, chips, and infrastructure enable intelligence generation at scale. Medical models, trained on clinical and biomedical data, interpret complex signals; applications then deliver value through radiology assistance, drug discovery, and clinical workflow automation. Viewpoint B: Not entirely The stack shows how capability is produced, but impact depends on translating that capability into clinical use. Strict validation, regulation, and the need to integrate with hospital workflows slow translation; consequently, healthcare applications often scale more slowly than the underlying AI stack. 👇Drop A or B and share your perspective

🩺 Community Question: In medical innovation, what drives greater long-term impact: U.S.-grade quality for rigorous validation and strict regulation or Asia-speed execution for faster approvals and rapid scale? Viewpoint A: U.S.-Grade Quality Through institutions like the U.S. Food and Drug Administration, the U.S. emphasizes deep clinical validation before approval. Rigor reduces risk, protects trust, and supports durable breakthrough innovation. Viewpoint B: Asia-Speed Execution Countries such as China and India accelerate approvals and deploy innovations at scale. Faster access can save lives, especially in high-burden diseases. 👇 Drop A or B and share your perspective.

💊 Community Question: Can AI help discover and develop new medicines much faster and cheaper than traditional methods? Viewpoint A: Yes. AI can rapidly test millions of drug ideas, cut early research time and costs dramatically, and in some cases bring medicines to patients years faster. Viewpoint B: Not fully. AI helps at the start, but human trials are still slow, expensive, and unpredictable, keeping overall drug development costly and time-consuming. If AI is expected to change how medicines are made, is the impact already real or mostly promise? 👇 Drop A, B, or share your perspective.

🩺 Community Question Is personalized care realistic for low- and middle-income countries (LMICs), or is it still a model built mainly for high-income countries (HICs)? Viewpoint A: Gradually achievable in LMICs Personalized care can scale over time. Costs of genetic and digital tools are falling, AI-driven insights are becoming more accessible, and hybrid models already work in areas like oncology and chronic care. With the right partnerships and focus, personalization doesn’t have to remain a luxury. Viewpoint B: Not practical for most LMICs For many LMICs, personalized care remains unrealistic. High costs, limited infrastructure, workforce gaps, and unequal access make large-scale adoption difficult. Healthcare systems should prioritize proven, low-cost interventions like vaccination, screening, and basic prevention. Or is the future of healthcare built by combining both approaches? 👇 Drop A, B, or share your perspective. Tag someone who should weigh in on this.